Neuron specific enolase and prognosis of non-small cell lung cancer: A systematic review and meta-analysis

被引：3

作者：

Yan, Hai-Jun ^{[1
]}

Tan, Yan ^{[1
]}

Gu, Wei ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliatted Nanjing Hosp, Dept Resp Med, Nanjing, Jiangsu, Peoples R China

来源：

JOURNAL OF BUON | 2014年 / 19卷 / 01期

关键词：

meta-analysis; non-small cell lung cancer; prognosis; serum neuron-specific enolase; TUMOR-MARKERS; CHEMOTHERAPY; NSE; SURVIVAL; CYFRA-21-1; CARCINOMA; CEA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The predictive and prognostic role of neuron-specific enolase (NSE) in non-small cell lung cancer (NSCLC) is still under debate. The present meta-analysis aimed to evaluate the relation between serum NSE levels and the prognosis of NSCLC. Methods: We performed a meta-analysis of published studies assessing the association of NSE with the prognosis of NSCLC. Literature retrieval, trials' selection and assessment, data collection, and statistical analysis were performed according to the Revman 5.0 guidelines. A fixed-effect model was used to pool the hazard ratio (HR) and 95% confidence intervals (95% CIs). Results: A total of 8 eligible studies that included 2389 NSCLC patients were analyzed. We did not find prognostic value of NSE for NSCLC (HR=1.17, 95% CI: 0.95-1.44, p=0.14). Conclusion: The present study indicated that serum NSE level is of no prognostic significance in patients with NSCLC.

引用

页码：153 / 156

页数：4

共 23 条

[1] SERUM NEURON-SPECIFIC ENOLASE LEVEL AS A PROGNOSTIC FACTOR IN NONSMALL CELL LUNG-CANCER [J].

ANDOH, M ;

GEMMA, A ;

TAKENAKA, K ;

HISAKATSU, S ;

YAMADA, K ;

USUKI, J ;

HASEGAWA, K ;

SAKONJI, M ;

KUDOH, S ;

TSUBOI, E ;

NIITANI, H .

INTERNAL MEDICINE, 1994, 33 (05) :271-276

[2]

[Anonymous], 2008, REV MAN REVMAN COMP

[3] Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer [J].

Barlési, F ;

Gimenez, C ;

Torre, JP ;

Doddoli, C ;

Mancini, J ;

Greillier, L ;

Roux, F ;

Kleisbauer, JP .

RESPIRATORY MEDICINE, 2004, 98 (04) :357-362

[4]

CARNEY DN, 1982, LANCET, V1, P583

[5] Prognostic value of histology in patients with non-small cell lung cancer [J].

Charloux, A ;

Hedelin, G ;

Dietemann, A ;

Ifoundza, T ;

Roeslin, N ;

Pauli, G ;

Quoix, E .

LUNG CANCER, 1997, 17 (01) :123-134

[6]

DIEZ M, 1993, ONCOLOGY, V50, P127

[7] PROGNOSTIC FACTORS IN NONSMALL CELL LUNG-CANCER [J].

FELD, R ;

BORGES, M ;

GINER, V ;

GINSBERG, R ;

HARPER, P ;

KLASTERSKY, J ;

LACQUET, L ;

PAESMANS, M ;

PAYNE, D ;

ROSELL, R ;

SAUSE, W ;

SCULIER, JP ;

SHAW, E ;

SORENSEN, JB ;

SPLINTER, T ;

STAHEL, R ;

BUNN, P .

LUNG CANCER, 1994, 11 :S19-S23

[8] Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: A Cancer and Leukemia Group B study [J].

Graziano, SL ;

Kern, JA ;

Herndon, JE ;

Tatum, A ;

Brisson, ML ;

Memoli, V ;

Sugarbaker, D ;

Skarin, AT ;

Kreisman, H ;

Green, MR .

LUNG CANCER, 1998, 21 (03) :203-211

[9] Cancer statistics, 2007 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Murray, Taylor ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66

[10] The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer [J].

Jin, Bo ;

Huang, Ai-mi ;

Zhong, Run-bo ;

Han, Bao-hui .

CHEMOTHERAPY, 2010, 56 (06) :417-423

← 1 2 3 →